Neurocrine Biosciences | NBIX - Net Income


Neurocrine Biosciences reported $144.4M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
ALKERMES USD 501K 66.98M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Exelixis USD 210.47M 34.06M Mar/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Prothena USD 32.72M 54.31M Mar/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Repligen USD 5.01M 3.32M Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Teva Pharmaceutical Industries USD -576M 945M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026